title: Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.
authors.forename: Gunjan
authors.initials: G
authors.lastname: Sinha
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001549:Benzamides / Q000008:administration & dosage / Q000494:pharmacology*; D015982:Bias; D016190:Carboplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D015507:Drugs, Investigational / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D058990:Molecular Targeted Therapy / Q000379:methods; D010051:Ovarian Neoplasms / Q000188:drug therapy; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D012107:Research Design; D017211:Treatment Failure; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D000093542:Gemcitabine
chemical_list: D001549:Benzamides; D015507:Drugs, Investigational; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D003841:Deoxycytidine; C090712:iniparib; D016190:Carboplatin; D000093542:Gemcitabine